Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Stricture, and Research and clinical trials. The original article is from firstwordpharma.com.

Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Infliximab, and Ustekinumab.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Depression, and Research and clinical trials. The original article is from Cellular and Molecular...

This case shows that routine pre-biologic screening can reveal other granulomatous disease (pulmonary sarcoidosis) that may affect treatment choice. It also illustrates that infliximab (an anti-TNF) was used with...

Perianal fistulas in Crohn’s disease are often hard to treat; this review suggests stem cell therapies can produce durable closure for many patients and appear safe over 1–4 years of follow-up.

A dedicated Digestive Health Centre could make it easier for people with IBD (including children and teens) to access coordinated care—fewer separate visits and more centralized specialist services in one location.

Cure8 found this source from cbsnews.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Pediatrics and family. Open the original article for the full...

People with IBD are at higher risk for shingles; this study suggests the recombinant zoster vaccine reduces that risk and did not increase short-term IBD flares in the populations studied. That could inform vaccine...

This study provides real-world data suggesting the oral α4-integrin antagonist carotegrast methyl can improve patient-reported stool frequency and rectal bleeding in many people with ulcerative colitis who did not...

A Meckel diverticulum can present like Crohn’s disease and may be the true cause when IBD treatment fails; identifying it can lead to a surgical cure for symptoms such as anemia and obstruction.

The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...

Cure8 could only read part of this source from manilatimes.net, so this card uses cautious topic tags instead of a full summary. It is tagged for Access, cost, and policy.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Fistula, and Complications. The original article is from Journal of gastrointestinal and liver diseases : JGLD.

Many IBD patients in this survey expressed concern about climate change and willingness to support sustainable healthcare options—information that could influence how care pathways, device reuse, or treatment-choice...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Anti-TNF, and Medications. The original article is from Journal of gastrointestinal and liver diseases :...

Faster, lower-cost intestinal ultrasound at the bedside could make imaging more accessible for children with IBD and shift how flare assessments are done, but real-world adoption requires training and coordination with...

Fatigue greatly affects quality of life for people with IBD even in remission; if effective and scalable, a mobile CBT program could offer accessible symptom support. The trial will also examine engagement factors...

Self-management programs that teach cognitive behavioral strategies, symptom tracking, relaxation, sleep and diet skills could help people with IBD manage symptoms and day-to-day quality of life without relying solely on...

This press release announces upcoming presentations of early clinical and biomarker data for PALI-2108, a gut‑targeted oral PDE4 prodrug being developed for UC and Crohn’s disease. Patients and clinicians may see new...

Cure8 found this source from note.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Steroids. Open the original article for the full details.

This preclinical study suggests a heat‑inactivated probiotic strain reduced colitis signs in mice and changed gut microbes and inflammatory pathways—findings that could inform future research into microbiome‑based or...

This preclinical study suggests a specific probiotic strain (Lp05) can increase regulatory T cells and reduce inflammation in a mouse colitis model, which could point to new microbiome-based approaches for IBD in the...

The study suggests a specific macrophage pathway (TRPV1→miR‑31/Wnt16) by which high‑fat diets may worsen intestinal inflammation and fibrosis, offering possible targets for future IBD research relevant to patients with...

Metabolic interactions between epithelial and immune cells may help explain persistent inflammation and barrier problems in IBD and point to new therapeutic targets that could complement current immune-targeting drugs.

The review links changes in the microbiome and microbial polyamine production to immune cell imbalance that can drive both oral inflammation and IBD. Understanding this pathway could point to new research directions and...

ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.

Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.

Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...

The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...

A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.

This study suggests that even when people with IBD are in clinical and biological remission on long-term biologic therapy, their gut microbiome composition and inferred functions can still differ from laboratory...

AI-assisted detection tools and disease-specific optical classifications could improve lesion detection and real-time characterization during UC surveillance, potentially affecting surveillance accuracy and...

Colon-targeted prednisolone devices could lower upper-GI exposure to steroids and provide sustained local therapy, which may be relevant for IBD treatment strategies if later validated in vivo and in clinical trials.

Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...

If you or your clinician are considering switching from IV to subcutaneous vedolizumab, this multicentre cohort suggests most patients (about 84%) remain on the subcutaneous formulation at one year. The switch appears...

The case links thymic hyperplasia, thyroid autoimmunity, and severe UC with colorectal neoplasia, suggesting possible shared immune dysregulation that might interest patients and clinicians, but it does not support...

Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Canadian Medical Association Journal.

Abnormal liver tests are common in children with IBD and can come from many causes, including the disease itself or the medicines used to treat it. A practical approach helps avoid stopping effective IBD therapy...

A rare but serious neurological complication (Guillain–Barré syndrome) occurred alongside a severe UC flare after abrupt vedolizumab withdrawal, so people with UC should be aware that sudden neurologic weakness needs...

If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.

Fatigue markedly affects quality of life for people with Crohn’s and often remains after inflammation is controlled. Recognizing multiple drivers — psychological distress and immune/hematologic signals — could change how...

If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...

m6A RNA methylation is a regulator of RNA function that may influence inflammation, immunity, and the intestinal microbiota — all central to IBD. Understanding these pathways could identify new biomarkers or drug targets...

Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization...

Finding genetic variants that correlate with country-level IBD burden could help researchers study why IBD rates differ geographically and point to biological pathways relevant to disease risk and outcomes.

This study describes a novel, non‑drug HA‑based nano‑assembly that targets inflammatory M1 macrophages and reshapes the colonic immune environment in mouse models of ulcerative colitis — a potential new therapeutic...

New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...

This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...